Table 2.
Clinical and laboratory features of patients with CALR E381A
| Case | Gender/Age | Diagnosis | Coexistence | WBC (109/L) | HB (g/L) | PLT (109/L) | Thrombosis related events | Splenomegaly |
|---|---|---|---|---|---|---|---|---|
| 1 | M/53 | PV | JAK2 V617F | 10.3 | 236. | 751 | N | Y |
| 2 | F/55 | PV | JAK2 V617F | 9.4 | 191 | 306 | Cerebral thrombosis | N |
| 3 | M/59 | PV | JAK2 V617F | 14.9 | 212 | 273 | N | Y |
| 4 | F/69 | PV | JAK2 V617F | 8.5 | 180 | 403 | Myocardial infarction | N |
| 5 | M/53 | PV | N | 4.02 | 191 | 119 | Calf vein thrombosis | N |
| 6 | M/57 | PV | N | 6.41 | 196 | 173 | N | N |
| 7 | M/65 | PV | N | 5.92 | 187 | 178 | N | Y |
| 8 | M/50 | PV | N | 4.04 | 198 | 212 | N | N |
| 9 | M/71 | ET | JAK2 V617F | 9.73 | 152 | 861 | N | N |
| 10 | F/30 | ET | JAK2 V617F | 9.5 | 132 | 740 | Habitual abortion | Y |
| 11 | F/47 | ET | JAK2 V617F | 9.3 | 125 | 613 | N | N |
| 12 | F/32 | ET | JAK2 V617F | 10.5 | 153 | 1544 | N | Y |
| 13 | F/22 | ET | p.K385fs*47 (type-2) | 10.3 | 191 | 751 | N | Y |
| 14 | M/73 | ET | MPL W515L | 4.42 | 129 | 1082 | Intestinal bleeding | Y |
| 15 | M/41 | ET | N | 11.2 | 141 | 1474 | N | Y |
| 16 | F/69 | PMF | N | 15.1 | 76 | 406 | Pulmonary embolism | Y |
| 17 | F/54 | PMF | JAK2 V617F | 16.5 | 116 | 711 | N | Y |
| 18 | M/62 | PMF | NRAS (p.Gly12Ser) | 29.9 | 107 | 116 | N | Y |
| 19 | M/50 | CML (ET) | BCR/ABL | 13.82 | 103 | 424 | N | Y |